Combination therapy for advanced stomach cancer after progression
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of fruquintinib (a pill that blocks blood vessel growth), sintilimab (an immunotherapy), and targeted radiation for people with stomach or GEJ cancer that has only a few new spots after at least one prior treatment. The goal is to see if this triple approach helps control the cancer better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or GEJ adenocarcinoma that has spread or is locally advanced, and it has gotten worse after at least one prior treatment.
- You have only a few spots of cancer that have progressed (oligometastatic).
- You are age 18 or older and able to care for yourself (ECOG performance status 0-1).
- Your major organs (kidneys, liver, bone marrow, heart) are working well enough based on standard blood and heart tests.
- You have not had a drug that blocks VEGF or VEGFR before, and you don’t have active autoimmune or uncontrolled infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (fruquintinib and sintilimab) plus standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination can help shrink or control the cancer.
This clinical trial is testing a combination of three drugs—sintilimab, fruquintinib, and standard chemotherapy—as a first treatment for advanced stomach cancer that cannot be surgically removed. The goal is to see if this combination can shrink the cancer enough to allow surgery, potentially improving outcomes.
This trial tests a combination of an oral targeted therapy (fruquintinib), an immunotherapy (PD-1 inhibitor), and chemotherapy (FOLFOX) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this triplet therapy helps control the cancer better than standard treatments.
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
Hear when a new Gastric Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.